Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...

A drug once designed for dengue virus, then quietly abandoned by industry, is suddenly back in the spotlight, and it may be ...

Hepatitis B virus (HBV) infects more than 250 million people worldwide and can lead to chronic liver disease and liver cancer ...

As antibiotic-resistant infections rise and are projected to cause up to 10 million deaths per year by 2050, scientists are ...

A newly identified virus–cell hybrid structure allows viruses to spread faster and more aggressively by hitching a ride on ...

Researchers at the Kanazawa University Graduate School of Medical Sciences report in PLOS Pathogens a novel role for the ...

UMBC scientists uncovered how enteroviruses initiate replication by assembling a conserved RNA–protein complex inside host cells. The team showed how viral and host proteins bind an RNA cloverleaf to ...

From respiratory infection to fatal neurological disease, EHV-1 demands rapid PCR diagnosis, and detection protocols impact ...

The death toll and economic damage associated with flu highlight its role as one of the most harmful viruses in history.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc.

Discover how a tiny RNA molecule serves as a molecular switch in viral infections, providing insights into phage biology.

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works.